In the BioHarmony Drug Report Database

"Preview" Icon

Ertugliflozin

Steglatro (ertugliflozin) is a small molecule pharmaceutical. Ertugliflozin was first approved as Steglatro on 2017-12-19. It has been approved in Europe to treat type 2 diabetes mellitus. The pharmaceutical is active against sodium/glucose cotransporter 2. In addition, it is known to target sodium/glucose cotransporter 1. Steglujan’s patent is valid until 2030-07-13 (FDA).

 

Trade Name

 

Steglatro
 

Common Name

 

ertugliflozin
 

ChEMBL ID

 

CHEMBL1770248
 

Indication

 

type 2 diabetes mellitus
 

Drug Class

 

Phlorozin derivatives, phenolic glycosides

Image (chem structure or protein)

Ertugliflozin structure rendering